|
|
Дата |
|---|
| 18.11.2026 |
| 17.11.2026 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
0.85
|
0.9433
|
0.83795
|
0.8201
|
0.9023
|
0.8891
|
|
|
69 457.10
|
578.00
|
|
0.78
|
0.89
|
0.7999
|
0.7507
|
0.8309
|
0.8223
|
|
|
101 383.50
|
672.00
|
|
0.7507
|
0.845
|
0.84
|
0.7744
|
0.84
|
0.7791
|
|
|
39 162.72
|
396.00
|
|
0.8088
|
0.89
|
0.83
|
0.7932
|
0.8499
|
0.8499
|
|
|
61 016.79
|
556.00
|
|
0.8006
|
0.88
|
0.88
|
0.8243
|
0.88
|
0.835
|
|
|
78 124.21
|
307.00
|
|
0.8106
|
0.91
|
0.86995
|
0.85245
|
0.9082
|
0.861
|
|
|
49 832.63
|
304.00
|
|
0.85
|
0.928
|
0.91
|
0.86
|
0.91
|
0.86
|
|
|
34 430.60
|
226.00
|
|
0.89
|
0.98
|
0.912
|
0.895
|
0.9344
|
0.9024
|
|
|
18 040.93
|
183.00
|
|
0.89
|
0.97
|
0.9041
|
0.88
|
0.9301
|
0.9097
|
|
|
45 363.34
|
345.00
|
|
0.903
|
0.989
|
1.01
|
0.90
|
1.01
|
0.90805
|
|
|
30 230.36
|
194.00
|
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
Показать все Скрыть| 20.08.2026 |
|
| 28.08.2024 |
|